<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842813</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A02663-52</org_study_id>
    <nct_id>NCT03842813</nct_id>
  </id_info>
  <brief_title>Safety and Performance Assessment of Drug-Eluting Stent CRE8 in Diabetic Patients</brief_title>
  <acronym>EVALU8</acronym>
  <official_title>Safety and Performance Assessment of Coronary Drug-Eluting Stent CRE8 : Post-market Observationnal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvimedica Medical Technologies France</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>EVAMED</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alvimedica Medical Technologies France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a 'real-world' study which evaluates the safety and performance of the coronary&#xD;
      DES-CRE8 in diabetic patients.&#xD;
&#xD;
      As routine care, each patient will be followed until 12 months after stent implantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 9, 2019</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is Target Lesion Failure (TLF) rate at 1 year</measure>
    <time_frame>1 year post implantation</time_frame>
    <description>The TLF is defined as cardiac deaths, heart attack in relation with the target vessel or revascularization of the target lesion.&#xD;
If a patient has at least one of these events, he will be considered as TLF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>MACE are defined as: revascularization of the target lesion, heart attack or cardiac deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non cardiac deaths at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Non cardiac deaths at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis at 1 year</measure>
    <time_frame>1 year</time_frame>
    <description>Certain or probable stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE) at 1 year in the sub-group of patients with a short planned dual-therapy</measure>
    <time_frame>1 year</time_frame>
    <description>MACE are defined as: revascularization of the target lesion, heart attack or cardiac deaths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non cardiac deaths at 1 year in the sub-group of patients with a short planned dual-therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Non cardiac deaths at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis at 1 year in the sub-group of patients with a short planned dual-therapy</measure>
    <time_frame>1 year</time_frame>
    <description>Certain or probable stent thrombosis</description>
  </secondary_outcome>
  <enrollment type="Actual">1030</enrollment>
  <condition>Diabetes</condition>
  <condition>Coronaropathy</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DES-CRE8</intervention_name>
    <description>Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting coronary stent. The absence of the polymer minimizes the risk of inflammation/thrombosis, while the propriety formulation enhances drug absorption.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participation to the study will be proposed to all diabetic patients corresponding to the&#xD;
        inclusion and exclusion criteria after implantation of one or more coronary stent CRE8.&#xD;
&#xD;
        Patients will be consecutively included to limit selection bias.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years old,&#xD;
&#xD;
          -  patient informed and agreed to participate,&#xD;
&#xD;
          -  patient with one or more lesions treated with one or more coronary stent CRE8,&#xD;
&#xD;
          -  patient with a diabete insulin dependent or non-insulin dependant.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant or breast-feading women,&#xD;
&#xD;
          -  patient who refused to participate,&#xD;
&#xD;
          -  patient with another lesion treated during the same intervention with a balloon alone&#xD;
             or with another stent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien Vandenwildenberg</last_name>
    <role>Study Chair</role>
    <affiliation>Alvimedica Medical France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique de l'Europe</name>
      <address>
        <city>Amiens</city>
        <zip>80090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Avignon</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Beauvais</name>
      <address>
        <city>Beauvais</city>
        <zip>60000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Convert</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <zip>01004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Brive</name>
      <address>
        <city>Brive-la-Gaillarde</city>
        <zip>19100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Chartres</name>
      <address>
        <city>Chartres</city>
        <zip>280018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Schweitzer</name>
      <address>
        <city>Colmar</city>
        <zip>68003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud-Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé de Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Simone Veil</name>
      <address>
        <city>Eaubonne</city>
        <zip>95602</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Essey-lès-Nancy</city>
        <zip>54270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Gonesse</name>
      <address>
        <city>Gonesse</city>
        <zip>95500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Haguenau</name>
      <address>
        <city>Haguenau</city>
        <zip>67500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint-Joseph Saint-Luc</name>
      <address>
        <city>Lyon</city>
        <zip>69365</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pont de Chaumes</name>
      <address>
        <city>Montauban</city>
        <zip>82000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Hilaire</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint-Quentin</name>
      <address>
        <city>Saint-Quentin</city>
        <zip>02321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint-Joseph</name>
      <address>
        <city>Trélazé</city>
        <zip>49800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Valence</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Vannes</name>
      <address>
        <city>Vannes</city>
        <zip>56017</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 11, 2019</study_first_submitted>
  <study_first_submitted_qc>February 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>May 6, 2021</last_update_submitted>
  <last_update_submitted_qc>May 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

